葛根芩连片降低非小细胞肺癌免疫相关不良事件:多中心随机对照试验
这项多中心、开放标签、随机对照试验纳入94例接受免疫检查点抑制剂(ICI)治疗的晚期非小细胞肺癌(NSCLC)患者,比较联合葛根芩连片(GQT)与单纯ICI联合化疗的疗效与安全性。结果显示GQT组免疫相关不良事件(irAEs)发生率显著低于对照组(31.91% vs. 59.57%,p=0.007,95%CI:0.137-0.741),且GQT组无多系统毒性发生。GQT组IL-6水平在3个治疗周期后显著下降(p<0.001),可能介导irAEs减少。
要点
- GQT联合ICI及化疗可显著降低晚期NSCLC患者irAEs发生率。
- GQT组未出现多系统毒性,对照组有3例(3/28,10.7%)。
- GQT组IL-6水平在3周期后显著下降,或为irAEs减少机制。
核心结论
- GQT显著降低接受ICI治疗的晚期NSCLC患者irAEs发生率,并延长irAEs中位发生时间,效应可能与下调IL-6相关。
研究设计与样本
- 多中心、开放标签、随机对照试验,2022年10月至2024年8月在中国四家医院随机分配94例患者至GQT组(n=47)或对照组(n=47)。
主要发现
- GQT组irAEs发生率为31.91%(15/47),对照组为59.57%(28/47),p=0.007,95%CI:0.137-0.741。
- GQT组无患者发生多系统毒性,对照组有3例(3/28,10.7%)。
- GQT组irAEs中位发生时间为14.9周,对照组为8.7周(p=0.807)。
- 在可评估缓解的患者中,GQT组客观缓解率(ORR)为48.9%(0例完全缓解,23例部分缓解,n=45),对照组为36.2%(1例完全缓解,16例部分缓解,n=43),p=0.211,95%CI:0.686-3.725。
- GQT组IL-6水平在3个治疗周期后显著下降(p<0.001)。
临床怎么用
- 对于接受ICI联合化疗的晚期NSCLC患者,可考虑联合GQT以降低irAEs发生率,并关注IL-6水平变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune related adverse events (irAEs) significantly compromise patients' quality of life and limit the application of immunotherapy. Gegen Qinlian Tablets (GQT), a classical Chinese herbal formula, have shown potential in mitigating irAEs. However, clinical evidence supporting the use of GQT as a synergy therapy for immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC) remains insufficient. PURPOSE: To evaluate the efficacy and safety of GQT in reducing the incidence of irAEs in NSCLC with ICI treatment. STUDY DESIGN: A multi-center, open-label, randomized controlled trial. METHODS: Eligible patients were randomly assigned (1:1) to receive ICI plus chemotherapy plus GQT (GQT group) or ICI plus chemotherapy alone (control group). The primary outcome was the incidence and severity of irAEs. Secondary outcomes included objective response rate (ORR) and disease control rate (DCR). Serum levels of interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) were assessed at baseline and after treatment. RESULTS: From October 2022 to August 2024, 94 participants were randomized to the GQT group (n = 47) or the control group (n = 47) at four hospitals in China. The incidence of irAEs was significantly lower in the GQT group than in the control group [31.91 % (15/47) vs. 59.57 % (28/47), p = 0.007, 95 % CI: 0.137-0.741]. No patient in the GQT group experienced multi-systemic toxicity, whereas 3 patients in the control group did (3/28, 10.7 %). The median onset time of irAEs in the GQT group was 14.9 weeks, and was 8.7 weeks in the control group (p = 0.807). Among response-evaluable patients, the ORR was 48.9 % (0 CR, 23 PR) in the GQT group (n = 45), and 36.2 % (1 CR, 16 PR) in the control group (n = 43) (p = 0.211, 95 % CI: 0.686-3.725). IL-6 level significantly decreased after 3 treatment cycles in the GQT group (p < 0.001), potentially contributing to the reduced incidence of irAEs. CONCLUSION: GQT significantly reduced the incidence of irAEs and prolonged the median onset time of irAEs in patients with advanced NSCLC receiving ICI therapy. The observed effects may be associated with the downregulation of IL-6. GQT showed promise as a synergistic treatment that mitigated irAEs and might enhance the therapeutic efficacy of ICIs.
引用
- Lu X, Wang A, Chen D, et al. Gegen Qinlian Tablets attenuate immune-related adverse events in NSCLC patients: A multi-center randomized controlled trial in China. Phytomedicine. 2025. PMID: 40561860. doi:10.1016/j.phymed.2025.156968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。